References
Berger NA, Chatterjee S, Schmotzer JA, Helms SR (1991) Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death. Proc Natl Acad Sci USA 88: 8740–8743
Berrios M, Osheroff N, Fisher PA (1985) In situ localization of DNA topoisomerase II, a major polypeptide component of theDrosophila nuclear matrix fraction. Proc Natl Acad Sci USA 82: 4142–4146
Bertrand R, Kerrigan D, Sarang M, Pommier Y (1991) Cell death induced by topoisomerase inhibitors: role of calcium in mammalian cells. Biochem Pharmacol 42: 77–85
Bertrand R, Sarang M, Jenkin J, Kerrigan D, Pommier Y (1991) Differential induction of secondary fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplifiedc-myc expression. Cancer Res 51: 6280–6285
Brill SJ, Sternglanz R (1988) Transcription-dependent DNA supercoiling in yeast DNA topoisomerase mutants. Cell 54: 403–411
Brill SJ, DiNardo S, Voelkel-Meiman K, Sternglanz R (1987) Need for DNA topoisomerase activity as a swivel for DNA replication for transcription of ribosomal RNA [published erratum appears in Nature 326(6115): 812]. Nature 326: 414–416
Bugg BY, Danks MK, Beck WT, Suttle DP (1991) Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci USA 88: 7654–7658
Bullock P, Champoux JJ, Botchan M (1985) Association of crossover points with topoisomerase I cleavage sites: a model for nonhomologous recombination. Science 230: 954–958
Capranico G, Kohn KW, Pommier Y (1990) Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res 18: 6611–6619
Capranico G, Zunino F, Kohn KW, Pommier Y (1990) Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA affinity and cytotoxicity. Biochemistry 29: 562–569
Champoux JJ (1990) Mechanistic aspects of type-I topoisomerases. In: Wang JC, Cozzarelli NR (eds) topology and its biological effects. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 217–242
Chang J-Y, Han F-S, Liu S-Y, Wang Z-Q, Lee K-H, Cheng Y-C (1991) Effect of 4-beta-arylamino derivatives of 4′-O-demethylepipodophyllotoxin on human DNA topoisomerase II, tubulin polymerization, KB cells, and their resistant variants. Cancer Res 51: 1755–1759
Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF (1991) Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51: 6039–6044
Chow KC, King CK, Ross WE (1988) Abrogation of etoposide-mediated cytotoxicity by cycloheximide. Biochem Pharmacol 37: 1117–1122
Chung TDY, Drake FH, Tan KB, Per SR, Crooke S, Mirabelli CK (1989) Characterization and immunological identification of cDNA clones encoding two human topoisomerase II isoenzymes. Proc Natl Acad Sci USA 86: 9431–9435
Crissman HA, Gadbois DM, Tobey RA, Bradbury EM (1991) Transformed mammalian cells are deficient in kinase-mediated control of progression through the G1 phase of the cell cycle. Proc Natl Acad Sci USA 88: 7580–7584
D'Arpa P, Machlin PS, Ratrie H III, Rothfield NF, Cleveland DW, Earnshaw WC (1988) cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment. Proc Natl Acad Sci USA 85: 2543–2547
D'Arpa P, Beardmore C, Liu LF (1990) Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50: 6919–6924
DiNardo S, Voelkel K, Sternglanz R (1984) DNA topoisomerase II mutant ofSaccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proc Natl Acad Sci USA 81: 2616–2620
Drake FH, Zimmerman JP, McCabe FL, Bartus HF, Per SR, Sullivan DM, Ross WE, Mattern MR, Johnson RK, Crooke ST, et al (1987) Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J Biol Chem 262: 16739–16747
Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK (1989) Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 28: 8154–8160
Duguet M, Lavenot C, Harper F, Mirambeau G, De Recondo AM (1983) DNA topoisomerase from rat liver: physiological variations. Nucleic Acids Res 11: 1059–1075
Earnshaw WC, Halligan B, Cooke CA, Heck MM, Liu LF (1985) Topoisomerase II is a structural component of mitotic chromosome scaffolds. J Cell Biol 100: 1706–1715
Fleischmann G, Pflugfelder G, Steiner EK, Javaherian K, Howard GC, Wang JC, Elgin SC (1984) Drosophila DNA topoisomerase I is associated with transcriptionally active regions of the genome. Proc Natl Acad Sci USA 81: 6958–6962
Fosse P, Rene B, Le Bret M, Paoletti C, Saucier J-M (1991) Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative. Nucleic Acids Res 19: 2861–2868
Ganapathi R, Grabowski D, Ford J, Heiss C, Kerrigan D, Pommier Y (1989) Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage. Cancer Commun 1: 217–224
Garg LC, DiAngelo S, Jacob ST (1987) Role of DNA topoisomerase I in the transcription of supercoiled rDNA gene. Proc Natl Acad Sci USA 84: 3185–3188
Gasser SM, Laemmli UK (1986) Cohabitation of scaffold binding regions with upstream/enhancer elements of three developmentally regulated genes ofD. melanogaster. Cell 46: 521–530
Giaever GN, Wang JC (1988) Supercoiling of intracellular DNA can occur in eukaryotic cells. Cell 55: 849–856
Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M (1989) DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046–1048
Halligan BD, Edwards KA, Liu LF (1985) Purification and characterization of a type II DNA topoisomerase from bovine calf thymus. J Biol Chem 260: 2475–2482
Heck MM, Hittelman WN, Earnshaw WC (1988) Differential expression of DNA topoisomerase I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 85: 1086–1090
Hinds M, Deisseroth K, Mayes J, Altschuler E, Jansen R, Ledley FD, Zwelling LA (1991) Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res 51: 4729–4731
Holm C, Goto T, Wang JC, Bolstein D (1985) DNA topoisomerase II is required at the time of mitosis in yeast. Cell 41: 553–563
Holm C, Covey JM, Kerrigan D, Pommier Y (1989) Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 49: 6365–6368
Hooper DC, Wolfson JS (1991) Mode of action of the new quinolones: new data. Eur J Clin Microbiol Infect Dis 10: 223–231
Hsiang YH, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873–14878
Hsiang YH, Wu HY, Liu LF (1988) Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 48: 3230–3235
Hsiang Y-H, Liu LF, Wall ME, Wani MC, Nicholas AW, Manikumar G, Kirschenbaum S, Silber R, Potmesil M (1989) DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res 49: 4385–4389
Hsiang Y-H, Lihou MG, Liu LF (1989) Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077–5082
Hsieh T (1983) Purification and properties of type II DNA topoisomerase from embryos ofDrosophila melanogaster. Methods Enzymol 100: 161–170
Huff AC, Ward RE, Kreuzer KN (1990) Mutational alterations of the breakage/resealing subunits of bacteriophage T4 DNA topoisomerase confers resistance to antitumor agent m-AMSA. Mol Gen Genet 221: 27–32
Hwong C-L, Wang C-H, Chen Y-J, Whang-Peng J, Hwang J (1990) Induction of topoisomerase II gene expression in human lymphocytes upon phytohemagglutinin stimulation. Cancer Res 50: 5649–5652
Jaxel C, Kohn KW, Pommier Y (1988) Topoisomerase I interaction with SV40 DNA in the presence and absence of camptothecin. Nucleic Acids Res 16: 11157–11170
Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y (1989) Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49: 1465–1469
Jaxel C, Capranico G, Kerrigan D, Kohn KW, Pommier Y (1991) Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem 266: 20418–20423
Jaxel C, Capranico G, Wasserman K, Kerrigan D, Kohn KW, Pommier Y (1991) DNA sequence at sites of topoisomerase I cleavage induced by camptothecin in SV40 DNA. In: Potmesil M, Kohn KW (eds) DNA topoisomerases in cancer. Oxford University Press. New York, pp 182–195
Johnson RK, McCabe FL, Faucette LF, Hertzberg RP, Kingsbury WD, Boehm JC, Caranfa MJ, Holden KG (1989) SK&F 10864, a water-soluble analog of camptothecin with broad-spectrum activity in preclinical tumor models. Proc Am Assoc Cancer Res 30: 623
Juan CC, Hwang JL, Liu AA, Whang-Peng J, Knutsen T, Huebner K, Croce CM, Zhang H, Wang JC, Liu LF (1988) Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q 12–13.2. Proc Natl Acad Sci USA 85: 8910–8913
Kaneda N, Nagata H, Furuta T, Yokokura T (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50: 1715–1720
Kaufmann SH (1989) Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 49: 5870–5878
Kerrigan D, Pommier Y, Kohn KW (1987) Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity. NCI Monogr 4: 117–121
Kim RA, Wang JC (1989) Function of DNA topoisomerases as replication swivels inSaccharomyces cerevisiae. J Mol Biol 208: 257–267
Kjeldsen E, Bonven BJ, Andoh T, Ishii K, Okada K, Bolund L, Westergaard O (1988) Characterization of a camptothecin-resistant human DNA topoisomerase I. J Biol Chem 263: 3912–3916
Kreuzer KN (1989) DNA topoisomerases as potential targets of antiviral action. Pharm Ther 43: 377–395
Kunimoto T, Nitta K, Tanaka T, Uebuara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987) Antitumor activity of 7-ethyl-10-[1-piperidino)-l-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47: 5944–5947
Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351–375
Long BH, Musial ST, Brattain MG (1984) Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship. Biochemistry 23: 1183–1188
Miller KG, Liu LF, Englund PT (1981) A homogeneous type II DNA topoisomerase from HeLa a cell nuclei. J Biol Chem 256: 9334–9339
Minford J, Pommier Y, Filipski J, Kohn KW, Kerrigan D, Mattern M, Michaels S, Schwartz R, Zwelling LA (1986) Isolation of intercator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II. Biochemistry 25: 9–16
Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS (1972) Phase 1 clinical trial of weekly and daily treatment with camptothecin (NSC-100800): correlation with preclinical studies. Biochemistry 56: 515–521
Muller MT, Pfund WP, Mehta VB, Trask DK (1985) Eukaryotic type I topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA. EMBO J 4: 1237–1243
Muller MT, Spitzner JR, DiDonato JA, Mehta VB, Tsutsui K, Tsutsui K (1988) Single-strand DNA cleavages by eukaryotic topoisomerase II. Biochemistry 27: 8369–8379
Newport J, Spann T (1987) Disassembly of the nucleus in the mitotic extracts: membrane vesiculization, lamin disassembly, and chromosome condensation are independent processes. Cell 48: 219–230
O'Connor PM, Kerrigan D, Bertrand R, Kohn KW, Pommier Y (1990) 10,11-Methylenedioxycamptothecin, a topoisomerase I inhibitor of increased potency: DNA damage and correlation to cytotoxicity in human colon carcinoma (HT-29) cells. Cancer Commun 2: 395–400
Osheroff N, Shelton ER, Brutlag DL (1983) DNA topoisomerase II fromDrosophila melanogaster. Relaxation of supercoiled DNA. J Biol Chem 258: 9536–9543
Pommier Y, Kohn KW (1989) Topoisomerase II inhibition by antitumor intercalators and demethylepipodophyllotoxins. In: Glazer RI (ed) Developments in cancer chemotherapy. CRC Press, Boca Raton, Florida, pp 175–196
Pommier Y, Zwelling LA, Kao-Shan CS, Whang-Peng J, Bradley MO (1985) Correlations between intercalator-induced DNA strand breaks and sister chromatid exchanges, mutations, and cytotoxicity in Chinese hamster cells. Cancer Res 45: 3143–3149
Pommier Y, Kerrigan D, Schwartz RE, Swack JA, McCurdy A (1986) Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res 46: 3075–3081
Pommier Y, Covey J, Kerrigan D, Mattes, W, Markovits J, Kohn KW (1987) Role of DNA intercalation in the inhibition of purified mouse leukemia (L1210) DNA topoisomerase II by 9-aminoacridines. Biochem Pharmacol 36: 3477–3486
Pommier Y, Kerrigan D, Covey JM, Kao-Shan CS, Whang-Peng J (1988) Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive (CD3F) and resistant (DC3F/9-OHE) Chinese hamster cells. Cancer Res 48: 512–516
Pommier Y, Capranico G, Orr A, Kohn KW (1991) Distribution of topoisomerase II cleavage sites in SV40 DNA and the effects of drugs. J Mol Biol 222: 909–924
Pommier Y, Capranico G, Orr A, Kohn KW (1991) Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine and teniposide. Nucleic Acids Res 19: 5973–5980
Pommier Y, Jaxel C, Kerrigan D, Kohn KW (1991) Structure activity relationship of topoisomerase I inhibition by camptothecin derivatives: evidence for the existence of a ternary complex. In: (eds) DNA topoisomerases in cancer. Oxford University Press, New York, pp 121–132
Porter SE, Champoux JJ (1989) The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucleic Acids Res 17: 8521–8532
Priel E, Showalter SD, Blair DG (1991) Inhibition of human immunodeficiency virus (HIV-1) replication in vitro by noncytotoxic doses of camptothecin, a topoisomerase I inhibitor. AIDS Res Hum Retroviruses 7: 65–72
Riou J-F, Lefevre D, Riou G (1989) Stimulation of the topoisomerase II induced cleavage sites in thec-myc protooncogene by antitumor drugs is associated with gene expression. Biochemistry 28: 9104–9110
Roberge M, Th'ng J, Hamaguchi J, Bradbury EM (1990) The topoisomerase II inhibitor VM-26 induces marked changes in histone H1 kinase activity, histones H1 and H3 phosphorylation, and chromosome condensation in G2 phase and mitotic BHK cells. J Cell Biol 111: 1753–1762
Ryan AJ, Squires S, Strutt HL, Johnson RT (1991) Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res 19: 3295–3300
Saulnier MG, Vyas DM, Langley DR, Doyle TW, Rose WC, Crosswell AR, Long BH (1989) E-ring desoxy analogues of etoposide. J Med Chem 32: 1418–1420
Schneider E, Lawson PA, Ralph RK (1989) Inhibition of protein synthesis reduces the cytotoxicity of 4′-(9-acridinylamino)methane-sulfon-m-anisidide without affecting DNA breakage and DNA topoisomerase II in a murine mastocytoma cell line. Biochem Pharmacol 38: 263–269
Shero JH, Bordwell B, Rothfield NF, Earnshaw WC (1986) High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science 231: 737–740
Sinha BK, Haim N, Dusre L, Kerrigan D, Pommier Y (1988) DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action. Cancer Res 48: 5096–5100
Sinha BK, Politi PM, Eliot HM, Kerrigan D, Pommier T (1990) Structure-activity relations, cytotoxicity and topoisomerase II dependent DNA cleavage induced by pendulum ring analogues of etoposide. Eur J Cancer 26: 590–593
Tamura H-O, Ikegami Y, Ono K, Sekimizu K, Andoh T (1990) Acidic phospholipids directly inhibit DNA binding of mammalian DNA topoisomerase I. FEBS Lett 261: 151–154
Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226: 466–468
Thurston LS, Irie H, Tani S, Han FS, Liu ZC, Cheng YC, Lee KH (1986) Antitumor agents: 78. Inhibition of human DNA topoisomerase II by podophyllotoxin and alpha-peltatin analogues. J Med Chem 29: 1547–1550
Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Whang-Peng J, Knutsen T, Huebner K, Croce CM, Wang JC (1988) Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci USA 85: 7177–7181
Uemura T, Ohkura H, Adachi Y, Morino K, Shiozaki K, Yanagida M (1987) DNA topoisomerase II is required for condensation and separation of mitotic chromosomes inS. pombe. Cell 50: 917–925
Wall ME (1983) A new look at older drugs in cancer treatment: natural products. Biosci Rep 11: 480A-489A
Wall ME, Wani MC, Cooke CE, Palmer KH, McPhail AT, Slim GA (1966) The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor fromCamptotheca acuminata. J Am Chem Soc 88: 3888–3890
Wang H-P, Rogler CE (1991) Topoisomerase I-mediated integration of hepadnavirus DNA in vitro. J Virol 65: 2381–2392
Wang JC (1985) DNA topoisomerases. Annu Rev Biochem 54: 665–697
Wang JC (1987) Recent studies of DNA topoisomerases. Biochim Biophys Acta 909: 1–9
Wang JC (1991) DNA topoisomerases: why so many? J. Biol Chem 266: 6659–6662
Wright SJ, Schatten G (1990) Teniposide, a topoisomerase II inhibitor, prevents chromosome condensation and separation but not decondensation in fertilized surf clam (Spisula solidissima) oocytes. Dev Biol 142: 224–232
Wu HY, Shyy SH, Wang JC, Liu LF (1988) Transcription generates positively and negatively supercoiled domains in the template. Cell 52: 433–440
Zhou B-Z, Bastow KF, Cheng Y-C (1989) Characterization of the 3′ region of the human DNA topoisomerase I gene. Cancer Res 49: 3922–3927
Zwelling LA, Hinds M, Chan D, Altschuler E, Mayes J, Zipf TF (1990) Phorbol ester effects on topoisomerase II activity and gene expression in HL-60 human leukemia cells with different proclivities towards monocytoid differentiation. Cancer Res 50: 7116–7122
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pommier, Y. DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother. Pharmacol. 32, 103–108 (1993). https://doi.org/10.1007/BF00685611
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685611